Jefferies raised the firm’s price target on Henry Schein (HSIC) to $80 from $77 and keeps a Hold rating on the shares. Management has a strong track record that suggests the company can navigate current industry headwinds, but Henry Schein was the best performing stock among dental peers in 2024 and valuation already reflects the company’s position in the market, the analyst tells investors in a note on the dental group.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HSIC:
- Ananym plans proxy fight to seek Henry Schein board directors, Reuters reports
- Henry Schein double upgraded to Buy from Underperform at BofA
- Henry Schein upgraded to Buy from Underperform at BofA
- Early notable gainers among liquid option names on December 11th
- GE Vernova initiated, Merck upgraded: Wall Street’s top analyst calls